These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20445346)

  • 1. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
    Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U
    J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
    Wolf P; Alt K; Bühler P; Katzenwadel A; Wetterauer U; Tacke M; Elsässer-Beile U
    Prostate; 2008 Feb; 68(2):129-38. PubMed ID: 18044731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
    Baiz D; Hassan S; Choi YA; Flores A; Karpova Y; Yancey D; Pullikuth A; Sui G; Sadelain M; Debinski W; Kulik G
    Neoplasia; 2013 Oct; 15(10):1172-83. PubMed ID: 24204196
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Michalska M; Schultze-Seemann S; Kuckuck I; Wolf P
    Anticancer Res; 2018 Jan; 38(1):61-69. PubMed ID: 29277757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer.
    Bühler P; Wetterauer D; Gierschner D; Wetterauer U; Beile UE; Wolf P
    Anticancer Res; 2010 Sep; 30(9):3373-9. PubMed ID: 20944111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.
    Wolf P; Gierschner D; Bühler P; Wetterauer U; Elsässer-Beile U
    Cancer Immunol Immunother; 2006 Nov; 55(11):1367-73. PubMed ID: 16547705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
    Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
    Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL.
    Liu Z; Feng Z; Zhu X; Xu W; Zhu J; Zhang X; Fan Z; Ji G
    Immunol Lett; 2013 Jan; 149(1-2):30-40. PubMed ID: 23026237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer.
    Michalska M; Schultze-Seemann S; Bogatyreva L; Hauschke D; Wetterauer U; Wolf P
    Oncotarget; 2016 Apr; 7(16):22531-42. PubMed ID: 26968813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
    Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
    Huang X; Bennett M; Thorpe PE
    Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.
    Noll T; Schultze-Seemann S; Kuckuck I; Michalska M; Wolf P
    Cancer Immunol Immunother; 2018 Mar; 67(3):413-422. PubMed ID: 29188305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.
    Sokolova EA; Zdobnova TA; Stremovskiy OA; Balalaeva IV; Deyev SM
    Biochemistry (Mosc); 2014 Dec; 79(12):1376-81. PubMed ID: 25716732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.
    Fitting J; Blume T; Ten Haaf A; Blau W; Gattenlöhner S; Tur MK; Barth S
    MAbs; 2015; 7(2):390-402. PubMed ID: 25760770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
    Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
    Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.
    Sokolova E; Guryev E; Yudintsev A; Vodeneev V; Deyev S; Balalaeva I
    Oncotarget; 2017 Mar; 8(13):22048-22058. PubMed ID: 28423549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.
    Liu W; Onda M; Kim C; Xiang L; Weldon JE; Lee B; Pastan I
    Protein Eng Des Sel; 2012 Jan; 25(1):1-6. PubMed ID: 22101015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.
    Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A
    J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.
    Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.